DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1484)

Category

1484 Biopharma Reports

    Type 2 diabetes and obesity are chronic diseases that affect millions of...
    Type 2 diabetes and obesity are chronic diseases that affect millions of Americans and represent a costly expense for the nation’s healthcare payers. In the effort to manage quality and costs associated with treating these conditions, many health insurers have turned to accountable...
    Last Updated 3 February 2016 The type 2 diabetes therapy market will rapidly...
    Last Updated 3 February 2016 The type 2 diabetes therapy market will rapidly expand over our 2014-2024 study period, fueled by the disease’s increasing prevalence and a high unmet need for drugs that can effectively control the disease in the long term. A rich pipeline of novel agents is...
    Last Updated 1 February 2016Biomarker- and histology-driven prescribing has...
    Last Updated 1 February 2016Biomarker- and histology-driven prescribing has become standard practice in the treatment of non-small-cell lung cancer (NSCLC). The treatment algorithms for NSCLC—including those for biomarker-defined patient subpopulations—continue to evolve, driven by the...
    LaunchTrends®: Inflectra/Remsima (Wave 2) is the second in a series of...
    LaunchTrends®: Inflectra/Remsima (Wave 2) is the second in a series of syndicated reports designed to track physician perception and uptake of Hospira’s Inflectra and Mundipharma’s Remsima, two different brands of Celltrion’s infliximab biosimilar CT-P13....
    Last Updated 15 January 2016A new era in the market for multiple sclerosis (MS)...
    Last Updated 15 January 2016A new era in the market for multiple sclerosis (MS) disease-modifying therapies (DMTs) has dawned: Novartis/Mitsubishi Tanabe Pharma’s fingolimod (Gilenya/Imusera) and Biogen’s dimethyl fumarate (Tecfidera) have partially fulfilled a pent-up demand for effective...
    Last Updated 11 January 2016Unipolar depression—comprising major depressive...
    Last Updated 11 January 2016Unipolar depression—comprising major depressive disorder (MDD), minor depression, and dysthymia—is a highly prevalent psychiatric disorder affecting nearly 85 million individuals in the seven major markets under study (United States, France, Germany, Italy,...
    Last Updated 16 December 2015 Schizophrenia is an often disabling psychiatric...
    Last Updated 16 December 2015 Schizophrenia is an often disabling psychiatric disease whose core treatment consists of years up to a lifetime of treatment with antipsychotics (older typical antipsychotics or newer atypical antipsychotics). With at least nine different atypical antipsychotic...
    Last Updated 18 December 2015The HIV therapy market is very dynamic. Over the...
    Last Updated 18 December 2015The HIV therapy market is very dynamic. Over the last decade, many effective antiretroviral (ARV) therapies have been introduced, prompting changes in treatment guidelines and clinical practices. In particular, highly effective and safe agents called integrase strand...
    Last Updated 8 December 2015 The hepatitis C virus (HCV) therapy market is...
    Last Updated 8 December 2015 The hepatitis C virus (HCV) therapy market is undergoing unprecedented growth. Commercial opportunity is driven by a large prevalent population and historically high unmet medical need due to the suboptimal efficacy and tolerability of interferon-based therapies. Between...
    Last Updated 28 September 2015The market for Alzheimer’s disease (AD)...
    Last Updated 28 September 2015The market for Alzheimer’s disease (AD) pharmacotherapies offers enormous commercial opportunity driven by considerable unmet need and looming societal burden. The AD population is poised to grow rapidly over the next ten years as the baby boomer generation...
    Last Updated 16 December 2015Parkinson’s disease (PD) is one of the most...
    Last Updated 16 December 2015Parkinson’s disease (PD) is one of the most common chronic neurodegenerative diseases in the elderly; its prevalence is expected to grow 2% annually in the major pharmaceutical markets. The market for PD pharmacotherapies features a high rate of polypharmacy that...
    Last Updated 23 December 2015Gram-negative infections (GNIs) account for a large...
    Last Updated 23 December 2015Gram-negative infections (GNIs) account for a large portion of hospital-treated infections (HTIs), which represent a high-value segment of the antibacterial market given the severity of these infections. In the past, developers have focused heavily on anti-gram-positive...
    Last Updated 22 October 2015The drug treatment of prostate cancer has evolved...
    Last Updated 22 October 2015The drug treatment of prostate cancer has evolved rapidly over the last few years—the metastatic castrate-resistant prostate cancer (mCRPC) setting has become crowded and competitive following the launch of five efficacious therapies since 2010, and the hormonal...
    Last Updated 4 December 2015 The term dyslipidemia refers to abnormalities in...
    Last Updated 4 December 2015 The term dyslipidemia refers to abnormalities in the composition, concentration, or size of lipoproteins in the circulation. Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease, but has historically been underdiagnosed in patients because of its...
    Last Updated 2 November 2015Fueled by multiple label expansions of premium-...
    Last Updated 2 November 2015Fueled by multiple label expansions of premium-priced agents and the launch of four novel therapies, the NHL market will experience significant growth over the ten-year forecast period. This comes despite biosimilar erosion expected for rituximab, the patient share and...
    The malignant melanoma treatment landscape is dynamic and continues to undergo...
    The malignant melanoma treatment landscape is dynamic and continues to undergo significant changes. Since 2011, three immune checkpoint inhibitors and four BRAF- or MEK-targeted agents have gained regulatory approval for unresectable or metastatic malignant melanoma. Among the most-recent market...
    Last Updated 14 December 2015The rheumatoid arthritis (RA) therapy market has...
    Last Updated 14 December 2015The rheumatoid arthritis (RA) therapy market has matured to the point that TNF-α inhibitors have become firmly established as first-line biological agents, leaving non-TNF-α agents to largely compete for use in TNF-refractory patients. For emerging agents, the...
    Last Updated 29 December 2015Methicillin-resistant Staphylococcus aureus (MRSA)...
    Last Updated 29 December 2015Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen found in both the hospital and outpatient settings. The recent approvals of oritavancin (The Medicine Company’s Orbactiv), dalbavancin (Allergan’s Dalvance/...
    1 - 20 of 1484